Clinical Trial Update: Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV) [Phase 1]

View source ↗

Summary

A Phase 1 proof-of-concept trial evaluating EBP921 for hepatitis D (HDV) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis D

Drugs mentioned

• EBP921

Snippet

Sponsor: Eiger BioPharmaceuticals | Conditions: Hepatitis D | Phase 1 | Status: TERMINATED